Annual CFO
-$3.70 M
-$1.71 M-85.77%
31 December 2023
Summary:
Protagenic Therapeutics annual cash flow from operations is currently -$3.70 million, with the most recent change of -$1.71 million (-85.77%) on 31 December 2023. During the last 3 years, it has fallen by -$2.35 million (-174.60%). PTIX annual CFO is now -185.05% below its all-time high of $4.36 million, reached on 31 December 2008.PTIX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$185.70 K
+$1.37 M+88.03%
30 September 2024
Summary:
Protagenic Therapeutics quarterly cash flow from operations is currently -$185.70 thousand, with the most recent change of +$1.37 million (+88.03%) on 30 September 2024. Over the past year, it has increased by +$470.10 thousand (+71.68%). PTIX quarterly CFO is now -102.69% below its all-time high of $6.90 million, reached on 30 September 2008.PTIX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$4.54 M
+$470.10 K+9.38%
30 September 2024
Summary:
Protagenic Therapeutics TTM cash flow from operations is currently -$4.54 million, with the most recent change of +$470.10 thousand (+9.38%) on 30 September 2024. Over the past year, it has dropped by -$1.80 million (-65.73%). PTIX TTM CFO is now -186.48% below its all-time high of $5.25 million, reached on 30 June 2009.PTIX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PTIX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -85.8% | +71.7% | -65.7% |
| 3 y3 years | -174.6% | +82.7% | -67.3% |
| 5 y5 years | -245.8% | -200.5% | -602.5% |
PTIX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -174.6% | at low | -2.6% | +88.8% | -134.7% | +9.4% |
| 5 y | 5 years | -659.0% | at low | -200.5% | +88.8% | -830.6% | +9.4% |
| alltime | all time | -185.1% | +67.1% | -102.7% | +96.4% | -186.5% | +66.7% |
Protagenic Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$185.70 K(-88.0%) | -$4.54 M(-9.4%) |
| June 2024 | - | -$1.55 M(-6.5%) | -$5.01 M(+0.4%) |
| Mar 2024 | - | -$1.66 M(+45.0%) | -$4.99 M(+34.8%) |
| Dec 2023 | -$3.70 M(+85.8%) | -$1.14 M(+74.5%) | -$3.70 M(+35.2%) |
| Sept 2023 | - | -$655.80 K(-57.2%) | -$2.74 M(+4.6%) |
| June 2023 | - | -$1.53 M(+312.0%) | -$2.62 M(+35.4%) |
| Mar 2023 | - | -$371.80 K(+105.5%) | -$1.94 M(-2.9%) |
| Dec 2022 | -$1.99 M(-28.8%) | -$180.90 K(-66.2%) | -$1.99 M(-10.1%) |
| Sept 2022 | - | -$535.20 K(-36.8%) | -$2.22 M(-19.6%) |
| June 2022 | - | -$847.10 K(+96.7%) | -$2.76 M(+5.2%) |
| Mar 2022 | - | -$430.60 K(+6.3%) | -$2.62 M(-6.3%) |
| Dec 2021 | -$2.80 M(+107.5%) | -$405.10 K(-62.3%) | -$2.80 M(+3.1%) |
| Sept 2021 | - | -$1.08 M(+51.4%) | -$2.71 M(+25.9%) |
| June 2021 | - | -$710.40 K(+16.9%) | -$2.16 M(+35.5%) |
| Mar 2021 | - | -$607.70 K(+89.4%) | -$1.59 M(+18.0%) |
| Dec 2020 | -$1.35 M(+176.4%) | -$320.90 K(-38.0%) | -$1.35 M(+14.6%) |
| Sept 2020 | - | -$517.80 K(+255.4%) | -$1.18 M(+63.2%) |
| June 2020 | - | -$145.70 K(-60.0%) | -$721.30 K(+9.9%) |
| Mar 2020 | - | -$364.40 K(+143.9%) | -$656.40 K(+34.5%) |
| Dec 2019 | -$488.00 K(-54.4%) | -$149.40 K(+141.7%) | -$488.00 K(-24.5%) |
| Sept 2019 | - | -$61.80 K(-23.5%) | -$646.40 K(-13.1%) |
| June 2019 | - | -$80.80 K(-58.8%) | -$744.20 K(-26.2%) |
| Mar 2019 | - | -$196.00 K(-36.3%) | -$1.01 M(-5.9%) |
| Dec 2018 | -$1.07 M(-22.4%) | -$307.80 K(+92.9%) | -$1.07 M(-9.3%) |
| Sept 2018 | - | -$159.60 K(-53.7%) | -$1.18 M(-14.4%) |
| June 2018 | - | -$344.80 K(+33.1%) | -$1.38 M(+7.6%) |
| Mar 2018 | - | -$259.00 K(-37.9%) | -$1.28 M(-7.1%) |
| Dec 2017 | -$1.38 M(+21.0%) | -$417.00 K(+16.2%) | -$1.38 M(+5.8%) |
| Sept 2017 | - | -$358.80 K(+45.3%) | -$1.30 M(+5.0%) |
| June 2017 | - | -$246.90 K(-30.9%) | -$1.24 M(-13.8%) |
| Mar 2017 | - | -$357.40 K(+4.6%) | -$1.44 M(+26.3%) |
| Dec 2016 | -$1.14 M(+201.7%) | -$341.80 K(+15.4%) | -$1.14 M(+26.1%) |
| Sept 2016 | - | -$296.10 K(-33.5%) | -$904.60 K(+27.3%) |
| June 2016 | - | -$445.10 K(+675.4%) | -$710.50 K(+97.1%) |
| Mar 2016 | - | -$57.40 K(-45.8%) | -$360.40 K(-8.8%) |
| Dec 2015 | - | -$106.00 K(+3.9%) | -$395.00 K(-1.3%) |
| Sept 2015 | - | -$102.00 K(+7.4%) | -$400.00 K(+5.8%) |
| June 2015 | -$378.00 K(-52.2%) | -$95.00 K(+3.3%) | -$378.00 K(+2.2%) |
| Mar 2015 | - | -$92.00 K(-17.1%) | -$370.00 K(-6.1%) |
| Dec 2014 | - | -$111.00 K(+38.8%) | -$394.00 K(-9.2%) |
| Sept 2014 | - | -$80.00 K(-8.0%) | -$434.00 K(-45.1%) |
| June 2014 | -$790.00 K(+143.8%) | -$87.00 K(-25.0%) | -$790.00 K(+12.4%) |
| Mar 2014 | - | -$116.00 K(-23.2%) | -$703.00 K(+19.8%) |
| Dec 2013 | - | -$151.00 K(-65.4%) | -$587.00 K(+34.6%) |
| Sept 2013 | - | -$436.00 K(+489.2%) | -$436.00 K(-92.8%) |
| June 2013 | -$324.00 K(-97.1%) | - | - |
| Sept 2011 | - | -$74.00 K(-97.9%) | -$6.03 M(-35.4%) |
| June 2011 | - | -$3.55 M(-14.1%) | -$9.33 M(-14.9%) |
| Mar 2011 | - | -$4.13 M(-340.5%) | -$10.97 M(-2.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2010 | -$11.25 M(+273.1%) | $1.72 M(-150.9%) | -$11.25 M(-17.5%) |
| Sept 2010 | - | -$3.37 M(-34.9%) | -$13.63 M(+14.2%) |
| June 2010 | - | -$5.19 M(+17.7%) | -$11.94 M(+67.0%) |
| Mar 2010 | - | -$4.41 M(+559.7%) | -$7.15 M(+137.0%) |
| Dec 2009 | -$3.02 M(-169.2%) | -$668.00 K(-60.1%) | -$3.02 M(-9.3%) |
| Sept 2009 | - | -$1.68 M(+323.0%) | -$3.32 M(-163.3%) |
| June 2009 | - | -$396.00 K(+43.5%) | $5.25 M(+530.4%) |
| Mar 2009 | - | -$276.00 K(-71.7%) | $833.00 K(-80.9%) |
| Dec 2008 | $4.36 M(-183.6%) | -$976.00 K(-114.1%) | $4.36 M(+34.2%) |
| Sept 2008 | - | $6.90 M(-243.3%) | $3.25 M(-184.5%) |
| June 2008 | - | -$4.81 M(-248.3%) | -$3.84 M(+140.5%) |
| Mar 2008 | - | $3.25 M(-255.6%) | -$1.60 M(-69.3%) |
| Dec 2007 | -$5.21 M(-659.6%) | -$2.09 M(+1015.5%) | -$5.21 M(+66.8%) |
| Sept 2007 | - | -$187.00 K(-92.7%) | -$3.12 M(+5.7%) |
| June 2007 | - | -$2.57 M(+600.3%) | -$2.96 M(+275.8%) |
| Mar 2007 | - | -$367.00 K(+1753.5%) | -$786.80 K(+803.3%) |
| Dec 2006 | $931.00 K(-889.0%) | - | - |
| Oct 2006 | - | -$19.80 K(-95.0%) | -$87.10 K(-26.2%) |
| July 2006 | - | -$400.00 K(-207.5%) | -$118.00 K(-141.8%) |
| July 2006 | -$118.00 K(+168.2%) | - | - |
| Apr 2006 | - | $372.10 K(-1044.4%) | $282.00 K(-413.0%) |
| Jan 2006 | - | -$39.40 K(-22.3%) | -$90.10 K(+77.7%) |
| Oct 2005 | - | -$50.70 K(-94.3%) | -$50.70 K(-103.4%) |
| July 2005 | -$44.00 K(-94.8%) | - | - |
| July 2004 | -$842.00 K(-135.9%) | - | - |
| Apr 2003 | - | -$889.00 K(-151.4%) | $1.50 M(-56.4%) |
| Jan 2003 | - | $1.73 M(-424.8%) | $3.43 M(+69.9%) |
| Oct 2002 | - | -$532.00 K(-144.7%) | $2.02 M(-13.9%) |
| July 2002 | $2.35 M(+56.0%) | $1.19 M(+14.0%) | $2.35 M(-19.8%) |
| Apr 2002 | - | $1.04 M(+230.7%) | $2.92 M(+84.5%) |
| Jan 2002 | - | $316.00 K(-253.4%) | $1.58 M(+51.7%) |
| Oct 2001 | - | -$206.00 K(-111.6%) | $1.04 M(-30.5%) |
| July 2001 | $1.50 M(-57.1%) | $1.77 M(-700.0%) | $1.50 M(+13.8%) |
| Apr 2001 | - | -$295.00 K(+31.7%) | $1.32 M(-51.7%) |
| Jan 2001 | - | -$224.00 K(-188.5%) | $2.74 M(-25.2%) |
| Oct 2000 | - | $253.00 K(-84.1%) | $3.66 M(+4.4%) |
| July 2000 | $3.51 M(+959.8%) | $1.59 M(+41.8%) | $3.51 M(+43.1%) |
| Apr 2000 | - | $1.12 M(+60.0%) | $2.45 M(+235.3%) |
| Jan 2000 | - | $700.00 K(+600.0%) | $731.00 K(0.0%) |
| Oct 1999 | - | $100.00 K(-81.2%) | $731.00 K(+120.8%) |
| July 1999 | $331.00 K(-176.3%) | $531.00 K(-188.5%) | $331.00 K(-50.3%) |
| Apr 1999 | - | -$600.00 K(-185.7%) | $666.00 K(+17.7%) |
| Jan 1999 | - | $700.00 K(-333.3%) | $566.00 K(-206.0%) |
| Oct 1998 | - | -$300.00 K(-134.6%) | -$534.00 K(+23.0%) |
| July 1998 | -$434.00 K(-80.3%) | $866.00 K(-223.7%) | -$434.00 K(-66.6%) |
| Apr 1998 | - | -$700.00 K(+75.0%) | -$1.30 M(+116.7%) |
| Jan 1998 | - | -$400.00 K(+100.0%) | -$600.00 K(+200.0%) |
| Oct 1997 | - | -$200.00 K | -$200.00 K |
| July 1997 | -$2.20 M | - | - |
FAQ
- What is Protagenic Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Protagenic Therapeutics?
- What is Protagenic Therapeutics annual CFO year-on-year change?
- What is Protagenic Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Protagenic Therapeutics?
- What is Protagenic Therapeutics quarterly CFO year-on-year change?
- What is Protagenic Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Protagenic Therapeutics?
- What is Protagenic Therapeutics TTM CFO year-on-year change?
What is Protagenic Therapeutics annual cash flow from operations?
The current annual CFO of PTIX is -$3.70 M
What is the all time high annual CFO for Protagenic Therapeutics?
Protagenic Therapeutics all-time high annual cash flow from operations is $4.36 M
What is Protagenic Therapeutics annual CFO year-on-year change?
Over the past year, PTIX annual cash flow from operations has changed by -$1.71 M (-85.77%)
What is Protagenic Therapeutics quarterly cash flow from operations?
The current quarterly CFO of PTIX is -$185.70 K
What is the all time high quarterly CFO for Protagenic Therapeutics?
Protagenic Therapeutics all-time high quarterly cash flow from operations is $6.90 M
What is Protagenic Therapeutics quarterly CFO year-on-year change?
Over the past year, PTIX quarterly cash flow from operations has changed by +$470.10 K (+71.68%)
What is Protagenic Therapeutics TTM cash flow from operations?
The current TTM CFO of PTIX is -$4.54 M
What is the all time high TTM CFO for Protagenic Therapeutics?
Protagenic Therapeutics all-time high TTM cash flow from operations is $5.25 M
What is Protagenic Therapeutics TTM CFO year-on-year change?
Over the past year, PTIX TTM cash flow from operations has changed by -$1.80 M (-65.73%)